||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Eden Share Discussion Threads
Showing 2051 to 2069 of 2075 messages
|Cimpany evangelosta bigo Miiky Wilteresta has pistedo simea bullishi mitteringsa recentlyo sheepleo. Nithinga new Winderu howe the $3m dillar Piwerhouse twripentechi ire douingo. piii|
Is that written in pronunciation style Scottish?|
|Company evangelist. MW has posted some bullish mutterings recently sheeple. Nothing new. Winder how the £3m dollar powerhouse twrpenetech are doing. Pmsl|
|Sipcam Getting the word around Italia
|worth checking out Eden's recent tweets
'Sipcam Italia’s “3logy” (aka Eden’s 3AEY botryticide)- nearly sold out at a major dealer near Bari, Italy last week'
'Eden’s 3AEY treated 300 hectares of table grapes at this producer near Bari'
It's good to hear, the recent results did say things had gone well in Italy.
Just a shame it's all so frustratingly slow, things like Portugal and France approving 3AEY are outside Eden's control, but this deal for the nematicide is taking aeons. I know the deal has to be right and that these multi-nationals don't excactly hurry themselves, all the same.....|
|You most likely right about the tough market environment.
I'm glass half full on the RNS/results. Time will tell.|
|Exactly SS a lot of words to explain away the fact the market for edens products is a tough environment and end users not as interested as BoD would have shareholders believe.|
The financial results for the period alone do not really highlight the progress the business has made in the first six months of FY2016F, in our view. We believe Eden has made some significant steps forward in H1 from an operational standpoint most particularly in terms of gaining the required regulatory approvals in a number of countries to enable the sales of its product 3AEY via in-country partners. Encouragingly, the period also saw the first commercial sales of 3AEY. Looking forward, we expect the second half of the year to see a continuation of the positive operational momentum reported in H1 that should also deliver more material financial benefits to the business. The heavy weighting of revenue to H2 is in part a reflection of the timing of the botrytis season in Southern Europe which typically begins in August and extends through harvest to mid to late September.
Products evaluation update
From a financial perspective, it is Eden’s’ products and technologies under commercial evaluation that are the key drivers behind our forecasts for FY2016F. In that respect, we note management’s comments that negotiations in regard to its nematicide product are continuing with a multi-national industry leader and progress has been made towards a satisfactory conclusion. A final agreement is expected this year covering multiple territories around the world subject to further negotiation.
Furthermore, a number of evaluation projects for both Eden’s technologies and products are ongoing and we note Sean Smith, CEO’s comments
“I am pleased with the progress that is generally being made as well as with regulatory progress where territories such as the USA are now being actively pursued”.
Value potential becoming increasingly visible
Overall, we believe H1 2016A has been a further period of progress for Eden with further regulatory approval and the company gaining its first commercial sales. Going forward, we expect further progress in H2 and we are hopeful that this can include some positive newsflow in relation to the group’s nematicide product. Such progress would not only be positive from a financial perspective but it would also add diversification to the group thereby further reducing its risk profile whilst adding to its commercial credibility.
With a strong balance sheet in place post the capital raising and ongoing tight cost control, the company looks well placed to accelerate its development over the coming years. Based on our assumptions Eden’s shares are trading on an EV/EBITDA ratio for FY2017F of 9.9x, which is projected to fall to a lowly 3.3x in the following year. This suggests a compelling opportunity, in our view. House Stock.|
|Pmsl £110,000 revenues in 6 months thats not even the MD's monthly wage.|
|Did someone say Fraudulent technology ??
|SS off topic again. WTF is Frothy and what was the FRC letter ? Whats this got to do with performance of Eden in the field exactly ?Q12|
|SKLikely the interims will be released as soon as the company manages to produce some "good news," possibly the french approvals which the rampers will surely lap up and have Mike Walters doing cartwheels again.If I were a large investor here frankly would prefer to see chunky contracts sales and profits in place in existing markets rather than just more permissions to sell/licence. Why would you buy a share just because another large market opens up really puzzles me ? Surely you would much prefer evidence of widespread acceptance in Spain/Italy at this stage ?Q12|
|Artemis Alpha Trust keeping the faith along with LivingBridge
How many days?|
|www.airporttavern.co.uk Painter Pete 2300hrs on 5/8/16|
|RedhillWhere are the Bayer "rumours" mentioned ?|
|Hey ParanoidalsCheck the posts, it was a response to Mr Ramptastic creaming himself over Livingbridge raising new money as if this has any relevance to Eden.What 10% rise are you on about, the share price has actually slipped 20% from recent highs mid August.When do you think a trading update will be forthcoming chaps ?RegardsQ12|
|It isn't coincidence. There's no such thing.|
|Interesting that quazie reappears with his negative whines just after the Eden share price goes up 10% and rumours of Bayer activity.
Trying to talk the share price down, or simple coincidence?|